Shiow-Lin Pan

Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery
Professor, Master Program in Graduate Institute of Cancer Biology and Drug Discovery
Joint-Appointment Professor, Ph.D. Program in Drug Discovery and Development Industry
Joint-Appointment Professor, Master Program in Clinical Pharmacogenomics and Pharmacoproteomics
Member, TMU Biomedical Commercialization Center
Member, TMU Research Center of Cancer Translational Medicine

https://orcid.org/0000-0001-7449-3539

Emailslpan@tmu.edu.tw

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Education

2002 Ph.D. National Taiwan University
1994 M.S. Taipei Medical University

Experience

2020- Vice Dean, College of Medical Science and Technology, Taipei Medical University
2019- Director, Ph.D. Program in Drug Discovery and Development Industry, Taipei Medical University
2018- Professor, Master Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University
2016-2018 Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
2013-2016 Associate Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
2008-2013 Assistant Professor, Department of Pharmacology, Taipei Medical University
2009-2013 Assistant Investigator, National Health Research Institutes
2007-2009 Assistant Investigator, National Taiwan University
2002-2007 Postdoctor, National Taiwan Universiy
1994-1998 Teaching Assistant, Chang-Gung University

Research Interests

Drug Discovery
Disease animal model
Pharmacology

URL

http://acadsys.tmu.edu.tw/class/cv/cv2.asp?email=slpan&type=1

Awards

2019 Single Research Project Budget Award, Taipei Medical University

Fingerprint

Dive into the research topics where Shiow-Lin Pan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

12 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

2 Active
15 Finished

以體內及體外試驗來進行DYRK1B抑制劑之毒理學評估
Pan, S.
1/1/21 → 12/31/21
Project: B - Project of TMU › h - Higher Education Sprout Project
新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(3/3)
Pan, S.
8/1/20 → 7/1/21
Project: A - Government Institution › b - Ministry of Science and Technology
The Role of Protein Kinase CK1 and The Mechanism of Inhibitors on Glioblastoma Cells
Pan, S.
7/1/20 → 2/1/21
Project: A - Government Institution › b - Ministry of Science and Technology
以體內及體外試驗來進行SYRK1B抑制劑之毒理學評估
Pan, S.
1/1/20 → 12/31/20
Project: A - Government Institution › d - Ministry of Education
Drug Discovery and Pharmacological Investigation of Novel Selective Hdac Inhibitors as Anticancer Drugs
Pan, S.
8/1/19 → 7/31/20
Project: A - Government Institution › b - Ministry of Science and Technology

3454 Citations
35 h-Index
142 Article
6 Comment/debate

A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling
Chang, T. Y., Nepali, K., Chen, Y. Y., Yang, Y. C. S. H., Hsu, K. C., Yen, Y., Pan, S. L., Liou, J. P. & Lee, S. B., Jun 2021, In: Biomedicine and Pharmacotherapy. 138, 111485.
Research output: Contribution to journal › Article › peer-review

Open Access
EGFL6 promotes colorectal cancer cell growth and mobility and the anti‐cancer property of anti-EGFL6 antibody
Sung, T. Y., Huang, H. L., Cheng, C. C., Chang, F. L., Wei, P. L., Cheng, Y. W., Huang, C. C., Lee, Y. C., HuangFu, W. C. & Pan, S. L., Dec 2021, In: Cell and Bioscience. 11, 1, 53.
Research output: Contribution to journal › Article › peer-review

Open Access
Erratum: TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis (Theranostics (2019) 9:22 (6676-6689) DOI: 10.7150/thno.34020)
Huang, H. L., Liu, Y. M., Sung, T. Y., Huang, T. C., Cheng, Y. W., Liou, J. P. & Pan, S. L., Jan 1 2021, In: Theranostics. 11, 5, p. 2079 1 p.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
Identification of a dual TAOK1 and MAP4K5 inhibitor using a structure-based virtual screening approach
Chao, M. W., Lin, T. E., HuangFu, W. C., Chang, C. D., Tu, H. J., Chen, L. C., Yen, S. C., Sung, T. Y., Huang, W. J., Yang, C. R., Pan, S. L. & Hsu, K. C., Dec 2021, In: Journal of Enzyme Inhibition and Medicinal Chemistry. 36, 1, p. 98-108 11 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia
Yen, S. C., Chen, L. C., Huang, H. L., Ngo, S. T., Wu, Y. W., Lin, T. E., Sung, T. Y., Lien, S. T., Tseng, H. J., Pan, S. L., Huang, W. J. & Hsu, K. C., Jan 22 2021, In: Journal of Natural Products. 84, 1, p. 1-10 10 p.
Research output: Contribution to journal › Article › peer-review

The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H. (Contributor), Lin, Y. (Contributor), Chao, M. (Contributor), Sung, T. (Contributor), Wu, Y. (Contributor), Chen, Y. (Contributor), Lin, M. (Contributor), Liou, J. (Contributor), Pan, S. (Contributor) & Yang, C. (Contributor), Unknown Publisher, Dec 29 2018
DOI: 10.6084/m9.figshare.c.4350887.v1, https://springernature.figshare.com/collections/The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/4350887/1
Dataset
Additional file 1 of Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury
Lin, C. (Contributor), Hsu, K. (Contributor), HuangFu, W. (Contributor), Lin, T. E. (Contributor), Huang, H. (Contributor) & Pan, S. (Contributor), Unknown Publisher, Mar 12 2020
DOI: 10.6084/m9.figshare.11992497.v1, https://springernature.figshare.com/articles/Additional_file_1_of_Investigating_the_potential_effects_of_selective_histone_deacetylase_6_inhibitor_ACY1215_on_infarct_size_in_rats_with_cardiac_ischemia-reperfusion_injury/11992497/1
Dataset
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, May 29 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://doi.org/10.6084%2Fm9.figshare.c.4522856.v1
Dataset
Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, May 29 2019
DOI: 10.6084/m9.figshare.8202896.v1, https://springernature.figshare.com/articles/Additional_file_4_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202896/1
Dataset
Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, May 29 2019
DOI: 10.6084/m9.figshare.8202887.v1, https://springernature.figshare.com/articles/Additional_file_2_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202887/1
Dataset